Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Prevalence and Characteristics of Cutaneous Mastocytosis in Adult-Onset Mastocytosis in the Skin

Pablo Palomo Rumschisky, Lucia Bolea, Blanca De Felipe, Beatriz Astibia Mahillo, Fernando Martín Moro, Jesus Villarrubia Espinosa, Valentín García Gutiérrez, Sr., Ander Arteagoitia, Monica Garcia-Cosio, David González-De-Olano, Asunción Ballester, Bibiana Pérez García, Almudena Santón, Laura Carpio, Pilar Herrera Puente, Maria Gemma Moreno Jimenez, Javier López, Miguel Piris-Villaespesa

Blood (2024) 144 (Supplement 1): 6654.

https://doi.org/10.1182/blood-2024-202097

Published: 2024

Journal Articles

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Blood (2024) 144 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2024-201407

Published: 2024

Journal Articles

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 1552.

https://doi.org/10.1182/blood-2024-201264

Published: 2024

Journal Articles

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 6135.

https://doi.org/10.1182/blood-2024-201316

Published: 2024

Journal Articles

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

Claudia Nuñez-Torron stock, Carlos Jiménez, Fernando Martín Moro, Juan Marquet, Miguel Piris-Villaespesa, Clara Lopez Hernandez, Alejandro Luna, Valentín García Gutiérrez, Sr., Anabelle Chinea, Maria Gemma Moreno Jimenez, Javier López, Pilar Herrera Puente

Blood (2024) 144 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2024-210576

Published: 2024

Journal Articles

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2024) 144 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2024-200280

Published: 2024

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Blood (2023) 142 (Supplement 1): 4234.

https://doi.org/10.1182/blood-2023-190296

Published: 2023

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Joaquin Martinez Lopez, Javier De La Cruz, Rodrigo Gil-Manso, Celina Benavente Cuesta, Lauren Benito, jose Angel Hernandez, Maria Regina Herraez, Pilar Herrera Puente, Mi Kwon, Keina Quiroz, Andres Arroyo, Adrian Alegre, María Pilar Llamas Sillero, Javier López Jiménez, Pedro Sanchez-Godoy, Rafael F. Duarte, Jose L. Diez Martin, Víctor Jiménez-Yuste, Julio Garcia-Suarez

Blood (2022) 140 (Supplement 1): 7924–7925.

https://doi.org/10.1182/blood-2022-169545

Published: 2022

Journal Articles

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study

Blood (2021) 138 (Supplement 1): 186.

https://doi.org/10.1182/blood-2021-152539

Published: 2021

Journal Articles

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Blood (2021) 138 (Supplement 1): 1302.

https://doi.org/10.1182/blood-2021-152353

Published: 2021

Journal Articles

Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia

Claudia Nunez-Torron, MD, Fernando Martin Moro, Juan Marquet Palomanes, Miguel Piris-Villaespesa, MD, Ernesto Roldan, Alejandro Luna, MD, Adolfo Saez, Valentín Garcia-Gutiérrez, MD PhD, Lucía Rubio, Maria Eulalia Rodriguez, Anabelle Chinea, MD, Ana Lario, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139954

Published: 2020

Journal Articles

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Pilar Martínez, MD, Tomás Palanques Pastor, Jose Luiz Lopez Lorenzo, MD, Javier Cornago Navascués, MD, Gabriela Rodriguez-Macías, MD, Isabel Cano, MD, Montserrat Arnan Sangerman, María-Belén Vidriales, MDPhD, Jesús Lorenzo Algarra, Maria Angeles Foncillas, Pilar Herrera Puente, Carmen Botella, Susana Vives, MD, Angela Figuera Alvarez, MD PhD, Laida Cuevas Palomares, Marta Sobas, MDPhD, Alejandro Contento-Gonzalo, MD, Rebeca Cuello, MD, María Elena Amutio Diez, MD, Maria Dunia De Miguel, MD, Begoña Navas, MD, Juan Miguel Bergua Burgues, MD, Teresa Bernal del Castillo, MD PhD, María Carmen Mateos Rodríguez, MD, Erik de Cabo López, MD, Ana Carolina Franco Villegas, MD, Raimundo García-Boyero, MD, Cristian Escolano Escobar, MD, Cristina Seri, MD, Carlos Cervero, MD, Alicia Roldán Pérez, Maria Lourdes Hermosin, MD, Marta Cervera, MD, María Teresa Olave, MD, Paola Sandra Villafuerte Gutierrez, MD, Almudena De Laiglesia, MD, Josefina Serrano, MD, María Josefa Najera Irazu, MD, Jose Luis Piñana Sanchez, Miguel Ángel Sanz, MD, Joaquin Martinez-Lopez, MD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138471

Published: 2020

Journal Articles

Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Claudia Nunez-Torron, MD, Juan Marquet Palomanes, Valentín Garcia-Gutiérrez, MD PhD, Adolfo Saez, Alejandro Luna, MD, Jesus Villarrubia, PhD, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141683

Published: 2020

Journal Articles

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-134296

Published: 2020

Journal Articles

Prognostic Impact of the Latency Time from the Administration of Cytotoxic Therapy to the Development of Therapy-Related Myeloid Neoplasms

Claudia Nunez-Torron, MD, Adolfo Saez, Berta Mercedes Michael Fernández, Irene Garcia-Garcia, Juan Marquet Palomanes, Miguel Piris-Villaespesa, MD, Jesus Villarrubia, PhD, Valentín Garcia-Gutiérrez, MD PhD, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141907

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Blood (2019) 134 (Supplement_1): 3325.

https://doi.org/10.1182/blood-2019-126507

Published: 2019

Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood (2019) 134 (Supplement_1): 2584.

https://doi.org/10.1182/blood-2019-125683

Published: 2019

NARROW

Prevalence and Characteristics of Cutaneous Mastocytosis in Adult-Onset Mastocytosis in the Skin

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Prognostic Impact of the Latency Time from the Administration of Cytotoxic Therapy to the Development of Therapy-Related Myeloid Neoplasms

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only